Cingulate Inc. (CINGW)

US — Healthcare Sector
Peers: CING  CELUW  NRSNW  EQRXW  DRMAW 

Automate Your Wheel Strategy on CINGW

With Tiblio's Option Bot, you can configure your own wheel strategy including CINGW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CINGW
  • Rev/Share 0.0
  • Book/Share 3165.9525
  • PB 0.0025
  • Debt/Equity 0.0056
  • CurrentRatio 1.8709
  • ROIC -0.9544

 

  • MktCap 16940395.0
  • FreeCF/Share -1266.3156
  • PFCF -0.0037
  • PE -0.0021
  • Debt/Assets 0.0027
  • DivYield 0
  • ROE -4.7325

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Cingulate Inc. (CINGW)

  • IPO Date
  • Website https://www.cingulate.com
  • Industry Biotechnology
  • CEO Dr. Shane J. Schaffer Pharm.D.
  • Employees 13
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.